Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability of up to 200 Days of Valganciclovir in Pediatric Kidney Transplant Recipients
2010-022514-47Phase 3Completed
- Sponsor
- Roche
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of valganciclovir in cytomegalovirus disease (CMV) and cytomegalovirus infection, sponsored by Roche. Primary endpoint: Tolerability of valganciclovir prophylaxis up to 200 days. Started May 2011; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus disease (CMV)cytomegalovirus infection
Beyond the preview
Go deeper on 2010-022514-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022514-47.